Alina Jucov

机构：Nicolae Testemițanu State University of Medicine and Pharmacy

发表论文 60 篇 · 总被引 564 次 · h-index 11

代表论文

• A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D (2025 · New England Journal of Medicine · 被引 14)
• OS-127 Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: preliminary results from the phase 2 SOLSTICE trial in non-cirrhotic and compensated cirrhotic participants (2024 · Journal of Hepatology · 被引 7)
• GS-010 Outcomes of 48 weeks of therapy and subsequent 24-week post-treatment period with tobevibart (VIR-3434) and elebsiran (VIR-2218) with or without pegylated interferon alfa-2a in chronic hepatitis B virus infection. Findings from the MARCH study (2025 · Journal of Hepatology · 被引 6)
• Global multi-societies endorsement of the MAFLD definition (2024 · Annals of Hepatology · 被引 6)
• TOP-251 Efficacy and safety of Bemnifosbuvir and Ruzasvir after 8 weeks of treatment in patients with chronic hepatitis C virus (HCV) infection (2025 · Journal of Hepatology · 被引 4)
• ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial (2026 · ˜The œLancet. Gastroenterology & hepatology · 被引 3)